Fig. 2: CZ-treated MSCs maintain low immunogenicity. | Cell Death & Disease

Fig. 2: CZ-treated MSCs maintain low immunogenicity.

From: Chlorzoxazone, a small molecule drug, augments immunosuppressive capacity of mesenchymal stem cells via modulation of FOXO3 phosphorylation

Fig. 2

a, b Representative flow cytometry analysis of T-cell activation marker CD69 (early stage)/CD25 (mid stage) activated by 50 μg/ml PHA for 24/48 h (left) and statistical histogram of CD69/CD25 expression on T cells (right) in different culture groups, respectively. c MTS assay of T cells proliferation in different culture groups for 4 days. d Histogram of gene expression of HLA-A, HLA-B, and HLA-C on MSCs treated by different regents for 24 h. e Histogram of gene expression of HLA-DQ and HLA-DR on MSCs treated by different regents for 24 h. f, g Representative flow cytometry test result of HLA-ABC/HLA-DR on MSCs treated by different regents for 24 h (left) and histogram of relative MFI (mean fluorescence intensity) of this flow cytometry test (right). *P < 0.05, **P < 0.01, ***P < 0.001, ns no significant difference.

Back to article page